FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising an antigen-binding construct which specifically binds to HER2, a pharmaceutical composition for killing or inhibiting growth of a HER2-expressing (HER2+) tumor cell, a pharmaceutical composition for use in treating a HER2-expressing (HER2+) tumor, a pharmaceutical composition for use in treating cancer, a method of treating a subject having a HER2-expressing (HER2+) tumor, a method of detecting or measuring the amount of HER2 in a sample, a method of suppressing, reducing or blocking transmission of a HER2 mediated signal in a cell, a method for killing or inhibiting growth of a HER2-expressing tumor cell, a method for producing the above construct, recovered polynucleotide (versions), vector (versions), isolated cell for expression of antigen-binding structure and set for cancer treatment.
EFFECT: invention extends the range of products specifically binding to HER2.
74 cl, 54 tbl, 44 ex, 47 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
